METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).
Authors:
- Caroline RobertCRCaroline Robert
- Keith T. FlahertyKFKeith T. Flaherty
- Peter HerseyPeter Hersey
- Paul D. NathanPNPaul D. Nathan
- Claus GarbeClaus Garbe
- Mohammed M. MilhemMohammed M. Milhem
- Lev V. DemidovLDLev V. Demidov
- Jessica C. HasselJessica C. Hassel
- Piotr RutkowskiPRPiotr Rutkowski
- Peter MohrPMPeter Mohr
- Reinhard DummerReinhard Dummer
- 20 May 2012
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (15_suppl) , LBA8509